IL2 and melanoma: Numerous clinical trials investigating the co-administration of IL-2 as an adjuvant with CAR-T cell therapy (NCT00924326, NCT00019136, NCT04119024, NCT03098355) have demonstrated improved persistence of CAR-T cells and long-lasting remissions in various tumor types including lymphoma, ovarian cancer, and melanoma (181).